Central Pharmaceutical JSC No2 (HSTC:DP2) Current Deferred Revenue: ₫0.00 Mil (As of . 20)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HSTC:DP2 Central Pharmaceutical JSC No2 HSTC:DP2
23 GF Score
Price ₫4,900.00
View Full Analysis

What is Central Pharmaceutical JSC No2 Current Deferred Revenue?

Central Pharmaceutical JSC No2 HSTC:DP2 23 Current Deferred Revenue is ₫0.00 Mil as of . 20. GuruFocus rates HSTC:DP2 with a GF Score™ of 23/100.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Central Pharmaceutical JSC No2's current deferred revenue for the quarter that ended in . 20 was ₫0.00 Mil.

Central Pharmaceutical JSC No2 Current Deferred Revenue Related Terms

Central Pharmaceutical JSC No2 Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Central Pharmaceutical JSC No2's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Central Pharmaceutical JSC No2 Current Deferred Revenue Chart

Central Pharmaceutical JSC No2 Annual Data
Trend
Current Deferred Revenue

Central Pharmaceutical JSC No2 Semi-Annual Data
Current Deferred Revenue
HSTC:DP2
23GF Score
Central Pharmaceutical JSC No2 HSTC:DP2
Current Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Revenue of ₫0.00 Mil mean?
Central Pharmaceutical JSC No2 (HSTC:DP2) has a Current Deferred Revenue of ₫0.00 Mil as of . 20. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Central Pharmaceutical JSC No2 and its competitors.
Is Central Pharmaceutical JSC No2's Current Deferred Revenue too high?
Central Pharmaceutical JSC No2's current Current Deferred Revenue is ₫0.00 Mil. Overall, Central Pharmaceutical JSC No2 has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Central Pharmaceutical JSC No2's Current Deferred Revenue compare to ?
Central Pharmaceutical JSC No2's Current Deferred Revenue of ₫0.00 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Healthcare Providers & Services company?
A good Current Deferred Revenue depends on the Healthcare Providers & Services industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Central Pharmaceutical JSC No2 and its competitors. Central Pharmaceutical JSC No2's current Current Deferred Revenue is ₫0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Central Pharmaceutical JSC No2 stock overvalued right now?
Central Pharmaceutical JSC No2 (HSTC:DP2) has a current Current Deferred Revenue of ₫0.00 Mil. The current Current Deferred Revenue is ₫0.00 Mil. Central Pharmaceutical JSC No2's overall GF Score™ is 23/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For Central Pharmaceutical JSC No2 (HSTC:DP2), the current Current Deferred Revenue is ₫0.00 Mil as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Central Pharmaceutical JSC No2 Business Description

Comparable Companies
Address No. 9 Tran Thanh Tong, Bach Dang Ward, Hai Ba Trung District, Hanoi, VNM
Central Pharmaceutical JSC No2 is engaged in the Trading of medicinal materials, pharmaceutical materials, chemicals, essential oils, modern medicines, traditional medicine drugs, cosmetics, and nutritious foods. Some of its products include Gentamycin injection solution 80; Genatreson Skin Cream; Ferimax Hard Capsules and others.
23GF Score

Get the complete analysis for HSTC:DP2

Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₫4,900.00
Price